SHARED PRESCRIBING GUIDELINE

Size: px
Start display at page:

Download "SHARED PRESCRIBING GUIDELINE"

Transcription

1 working in partnership with Kingston Richmond Wandsworth SHARED PRESCRIBING GUIDELINE Sutton & Merton Methylphenidate, Dexamfetamine and Atomoxetine for Attention Deficit Hyperactivity Disorder in patients under 18 years of age N.B. The eligibility criteria included here apply to new patients commencing treatment under this guideline & not to existing patients whose treatment was initiated under the previous version. However, monitoring and discontinuation criteria apply to all patients. NOTES to the GP The expectation is that these guidelines should provide sufficient information to enable GPs to be confident to take clinical and legal responsibility for prescribing these drugs. The questions below will help you confirm this: Is the patient s condition predictable? (Noting the progressive nature of Alzheimer s Disease) Do you have the relevant knowledge, skills and access to equipment to allow you to monitor treatment as indicated in this shared care prescribing guideline? Have you been provided with relevant clinical details including monitoring data? If you can answer YES to all these questions (after reading this shared care guideline), then it is appropriate for you to accept prescribing responsibility. If the answer is NO to any of these questions, you should not accept prescribing responsibility. You should write to the consultant within 14 days, outlining your reasons for NOT prescribing. If you do not have the confidence to prescribe, we suggest you discuss this with your local Trust/specialist service, who will be willing to provide training and support. If you still lack the confidence to accept clinical responsibility, you still have the right to decline. Your PCT pharmacist will assist you in making decisions about shared care. It would not normally be expected that a GP would decline to share prescribing on the basis of cost. The patient s best interests are always paramount Date first approved: February 2004 Approved on behalf of SWL PCTs by: South West London Mental Health Interface Prescribing Forum (membership details available from John Woolven, Chief Pharmacist, SWLStG) Prepared by: Dr Morris Zwi (CAMHS Consultant) for: South West London & St Georges MH Trust Drug and Therapeutics Committee South West London Mental Health Interface Prescribing Forum (incorporating the MH Trust and NHS Kingston, NHS Sutton & Merton, NHS Richmond and NHS Wandsworth) This box can be used to confirm that shared care has been agreed between the consultant and GP. Patient name: Patient ID / D.O.B: Drug Name: Consultant Name: Consultant Signature: Indication: GP Name: GP Signature: 1

2 Methylphenidate, Dexamfetamine and Atomoxetine in under 18s 1. CIRCUMSTANCES WHEN SHARED CARE IS APPROPRIATE Prescribing responsibility will only be transferred when the consultant and the GP are in agreement that the patient s condition is stable or predictable and in accordance with NICE guidance. The patients will only be referred back to the GP once the GP has agreed in each individual case and the hospital will continue to provide prescriptions until successful transfer of responsibilities as outlined below The hospital will provide the patient with a minimum initial supply of 4 weeks of medication 2. AREAS OF RESPONSIBILITY Consultant 1. To assess the patient and establish a diagnosis of attention-deficit hyperactivity disorder; to determine a management strategy and communicate this to the family & GP. The diagnosis must clearly be demonstrated through a detailed report outlining the current problems, developmental history and presence of core signs of ADHD. These must meet the diagnostic criteria of the DSM-IV or the ICD-10 (hyperkinetic disorder). 2. Consider and discuss ADHD drug treatment options with the parents / responsible adult for the children who meet the criteria laid-down in NICE guidelines of September This should include a discussion of the reasons for treatment, the possible adverse effects and the lack of information in relation to longer-term outcomes including effectiveness and adverse effects. 3. Ensure relevant baseline investigations are performed, documenting height, weight and blood pressure and pulse. 4. Initiate treatment with methylphenidate, dexamfetamine or atomoxetine and prescribe medication until the dose has been stabilised. During this time monitor the patient as required for symptom control and side effects. 5. Provide the GP with appropriate clinical information and individual patient information. This may need to be more comprehensive with atomoxetine as GPs have much less experience and familiarity with this medicine. 6. Be available to give advice to GP if the patient s condition changes and to ensure that procedures are in place for prompt specialist review. 7. Perform a review of the patient, including a review of the need for medication, at least annually on an ongoing basis. 8. Advise the GP when the treatment is being discontinued to assess the need for ongoing treatment and provide supervision and assessment of the child during these periods. GP 1. Review the patient in accordance with specialist advice. 2. Prescribe methylphenidate, dexamfetamine or atomoxetine once the treatment has been established, the patient stabilised on a particular dose of medication and the care of patient has been transferred and accepted. 3. Monitor height, weight and blood pressure and pulse six monthly. Send copies of the results to the specialist. Notify the specialist of any concerns. 4. Re-refer the patient or seek specialist advice from the psychiatrist or paediatrician if there is deterioration in ADHD symptomatology, behaviour, or adverse effects of medication. 5. Although misuse of methylphenidate and dexamfetamine is rare, the GP should alert the Specialist to previous misuse of drugs by the young person or family members if such information is known. This is particularly important because methylphenidate and dexamfetamine are controlled drugs. 6. To report any adverse drug reactions to the Medicines and Healthcare Products Regulatory Authority (MHRA) as part of the yellow card scheme. Continued below 2

3 Consultant 9. Liaise with the patient s school and suggest appropriate extra educational provision where necessary. 10. Where the drug is to be continued beyond the age of 18, the consultant will advise about the options for ongoing care within adult services for each patient s particular needs. GP 2. COMMUNICATION AND SUPPORT Hospital contacts: (the referral letter will indicate named consultant) Tel: Fax: Enter the contact details of your local Child & Adolescent Mental Health Service (CAMHS) Team Out of hours contacts & procedures: Specialist support/resources available to GP including patient information: The on-call psychiatrist at your local hospital can be contacted via the hospital switchboard: Springfield Sutton Tolworth Queen Mary s Roehampton Contact with Child Psychiatrist 2. References (see key references at the end of this document) 3. Information in the British National Formulary for Children (BNFc) 4. ADHD support groups e.g. or (both of whom receive sponsorship from the pharmaceutical industry) CLINICAL INFORMATION Indication(s) Place in therapy Therapeutic summary Attention-deficit hyperactivity disorder (which is broadly similar to hyperkinetic disorder) is defined by core signs of an excess of inattention, hyperactivity and impulsiveness. These are normal personality traits, so is important to establish that they are present to a greater extent than expected in children of a developmental stage, that they cause impairment (commonly in social or academic domains) and that they are pervasive across a range of situations. Affected children often have co-morbid conditions including conduct disorder, oppositional defiant disorder, depression, anxiety, tic disorders and other developmental disorders. Methylphenidate, dexamfetamine and atomoxetine are recommended in the September 2008 NICE Guidelines on ADHD as part of a comprehensive treatment program for attention-deficit hyperactivity disorder in children and adolescents. (See Atomoxetine is still currently mainly used as a second or third line option where significant adverse effects occur with stimulant treatment e.g. intolerable appetite suppression or emotional lability. Methylphenidate, dexamfetamine and atomoxetine reduce the ADHD core symptoms : excessive inattention, hyperactivity and impulsivity. Duration of treatment o Determined on an individual basis o Transition to adult psychiatric services to be managed on an individual case basis as currently the numbers are very few, but increasing. o Advice to Adult Psychiatrists is available from Child & Adolescent psychiatrists. 3

4 Dose and Route of Administration All preparations are for oral administration. Dosage and timing will depend upon the patient and the form of the medicine: Methylphenidate Standard / Immediate release preparations Ritalin 10mg tablets; Equasym 5mg, 10mg, 20mg tablets o Initiate at 5mg OD or BD; increase dosage if necessary weekly, by increments of 5-10mg per day o Usual maximum dosage 60mg per day Modified release preparations Concerta-XL 18mg, 27mg, 36mg MR tablets o Initiate at 18mg daily; increase dose gradually according to needs and response of the patient. o Usual maximum 54mg per da,y but may be increased to 2.1 mg/kg daily (max. 108 mg daily) by specialists Equasym XL 10mg, 20mg, 30mg MR capsules o Initiate at 10 mg once daily in the morning before breakfast, increased gradually if necessary o Usual maximum 60 mg daily, but may be increased to 2.1 mg/kg daily (max. 90 mg daily) by specialists Medikinet XL 10mg, 20mg, 30mg, 40mg MR tablets o Initiate at 10 mg once daily in the morning before breakfast, increased gradually if necessary o Usual maximum 60 mg daily, but may be increased to 2.1 mg/kg daily (max. 90 mg daily) by specialists Dosage equivalence (immediate release (IR) vs. modified release (MR)): 5mg TDS (IR) = 18mg OD Concerta XL 10mg TDS (IR) = 36mg OD Concerta XL 15mg TDS (IR) = 54mg OD Concerta XL 5mg BD (IR) = 10mg Equasym XL 10mg BD (IR) = 20mg Equasym XL 15mg BD (IR) = 30mg Equasym XL Dexamfetamine Dexedrine 5mg tablets (standard release) o Initiate at 2.5 mg daily for children aged 3 5 yrs and 5 10 mg daily for children over 6yrs. o Increase dose to a usual maximum of 20 mg per day as necessary. o May require 40 mg or more daily in older children / adolescents. Atomoxetine Strattera 10mg, 18mg, 25mg, 40mg, 60mg, 80mg capsules o o patients up to 70 kg body weight: initiate at a total daily dose of approximately 0.5mg/kg. Increase the dose gradually as required to recommended maintenance dose of approx. 1.2mg/kg/day. patients over 70 kg body weight: initiate at a total daily dose of 40mg. Increase the dose gradually as required to recommended maintenance dose of 80mg. The maximum recommended total daily dose is 100mg. 4

5 Summary of adverse effects (See Summary of Product Characteristics for full list) Very common: >1/10 Common: >1/100, <1/10 Uncommon: >1/1000, <1/100 Rare: >1/10,000, <1/1000 Very rare: <1/10,000 Very common: >1/10 Common: >1/100, <1/10 Uncommon: >1/1000, <1/100 Rare: >1/10,000, <1/1000 Very rare: <1/10,000 Adverse effect Frequency Management Modestly raised resting pulse and blood pressure Weight loss / reduced weight gain Neurological effects incl. tics, depression, emotional lability, dizziness, anxiety, nervousness, hostility, headaches Common Monitor BP at baseline, every 6 months thereafter and at every dose change. Use with caution in patients with underlying medical condition (especially cardiovascular) Common Monitor height & weight at baseline & annually. Refer to consultant for discontinuation or interruption of treatment if signs of weight loss / growth suppression Common Discuss with consultant and agree appropriate action Insomnia / somnolence Common Discuss sleep hygiene; discuss with consultant possible trial of a small bedtime dose of stimulant Convulsions Rare Discontinue and discuss with consultant Neuroleptic Malignant Rare Stop and urgently refer to A&E Syndrome Blood Disorders Very Rare Differential blood & platelet counts if patient has recurrent nose bleeds, bruising or infections. If abnormal discontinue & discuss with consultant Abnormal liver function Very Rare Measure LFTs if there are clinical signs of abnormal liver function. Discontinue & discuss with consultant Sudden Death Very Rare See below and references: Prevention: A complete history should be taken documenting family history of sudden cardiac death, unexplained death or arrhythmias prior to initiation of stimulant treatment Physical examination for the presence of heart disease must be undertaken prior to initiation of treatment. Specialist cardiac evaluation, including ECG, should be sought where a significant cardiac history or abnormal examination is found. Caution should be used when treating patients whose underlying medical conditions might be compromised by increased blood pressure or heart rate. Monitoring Requirements: o Blood pressure & pulse every 6 months o Height & weight annually or sooner if clinically indicated o No routine measurement of LFTs / FBC, but measure if clinically indicated 5

6 Clinically relevant drug interactions: (See Summary of Product Characteristics (SmPC) for full list) In practice, very few children are taking other regular medicines. o Stimulant drugs may exacerbate effects of sympathomimetic drugs and coumarins, inhibit the metabolism of SSRIs and tricyclics, increase plasma concentration of anticonvulsants and increase risk of hypertension when volatile liquid anaesthetic gases are used. o Atomoxetine should not be used with MAOIs; caution if used with medicines that may decrease seizure threshold, increase QT interval or inhibit CYP2D6 (e.g. fluoxetine, paroxetine, quinidine, terbinafine) Practical issues: Prescriptions for methylphenidate and dexamfetamine must comply with all the requirements for prescribing of Controlled Drugs Stimulant medicines can be abused. As such, the prescriber must bear in mind any factors relating to the child or other family members that may be of concern in this regard The Concerta XL tablet shell is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet Key references: NICE Guideline no. 72 September ments ). o British National Formulary for Children (accessed 10 November 2009) o Drug and Safety Update, Medicines and Healthcare Regulatory Agency website (accessed 10 November 2009) ate/con o Am J Psychiatry 166:9, September 2009 Editorial: Stimulant Treatment of ADHD and Risk of Sudden Death in Children o Gould MS et al Am J Psychiatry 2009; 166: Sudden Death and use of Stimulant Medications in Youths 6

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance

More information

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1

More information

Issue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist

Issue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist Title Document Type Issue no Shared care guidelines in the Treatment of Attention Deficit/ Hyperactivity Disorders Shared Care Guidelines and Information for GPs Clinical Governance Support Team Use Issue

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a

More information

If a specialist asks a GP to prescribe ADHD medication in relation to this disease, the GP should reply to this request as soon as practicable.

If a specialist asks a GP to prescribe ADHD medication in relation to this disease, the GP should reply to this request as soon as practicable. Shared Care Protocol for the Methylphenidate and the Management of Attention Deficit Hyperactivity Disorder (ADHD) for children from 4 years up to 17 years and 364 days 1.0 INTRODUCTION The medical assessment

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE Approval date: September 2018. Document review date: September 2021 or sooner if evidence/practice changes g SHARED CARE PRESCRIBING GUIDELINE Methylphenidate, atomoxetine, lisdexamfetamine, dexamfetamine

More information

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing

More information

Child and Adolescent Mental Health Services (CAMHS)

Child and Adolescent Mental Health Services (CAMHS) Child and Adolescent Mental Health Services (CAMHS) Effective shared care agreement (ESCA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with METHYLPHENIDATE This form must be completed

More information

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To

More information

Adult Neurodevelopmental Services. ADHD Shared Protocol

Adult Neurodevelopmental Services. ADHD Shared Protocol Adult Neurodevelopmental Services ADHD Shared Protocol Issue 1: April 2016 1 2 Adult Neurodevelopmental Service Shared Care Protocol for Adult Attention Deficit Hyperactivity Disorder (ADHD) 1. BACKGROUND

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: METHYLPHENIDATE Protocol number: CV 42

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: METHYLPHENIDATE Protocol number: CV 42 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: METHYLPHENIDATE Protocol number: CV 42 Indication: ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), HYPERKINETIC

More information

Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults

Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Shared Care Guideline: Prescribing Agreement Modafinil for Narcolepsy in adults Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no:

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It

More information

SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD

More information

ADHD/Hyperkinetic Disorder for Children & Young People (6-17 years) - Methylphenidate, Atomoxetine, Dexamfetamine and Lisdexamfetamine

ADHD/Hyperkinetic Disorder for Children & Young People (6-17 years) - Methylphenidate, Atomoxetine, Dexamfetamine and Lisdexamfetamine DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name: Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Attention Deficit Hyperactivity Disorder

More information

Prescribing Framework for Methylphenidate for Attention Deficit Hyperactive Disorder

Prescribing Framework for Methylphenidate for Attention Deficit Hyperactive Disorder Hull & East Riding Prescribing Committee Prescribing Framework for Methylphenidate for Attention Deficit Hyperactive Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)

More information

Portsmouth and South East Hampshire Area Prescribing Committee. Shared Care Agreement. Licensed ADHD Medications for the Treatment of Childhood ADHD

Portsmouth and South East Hampshire Area Prescribing Committee. Shared Care Agreement. Licensed ADHD Medications for the Treatment of Childhood ADHD Portsmouth and South East Hampshire Area Prescribing Committee Shared Care Agreement Licensed ADHD Medications for the Treatment of Childhood ADHD Produced by: Graham Brown, Children s and Younger Peoples

More information

Patient Details: Section B: To be completed by the GP and returned to the Specialist Clinician detailed above

Patient Details: Section B: To be completed by the GP and returned to the Specialist Clinician detailed above Shared Care Guideline Prescribing Agreement for single agent Attention Deficit Hyperactivity Disorder (ADHD) medication ATOMOXETINE in ADULT patients (over 18 years) Section A To be completed by the Specialist

More information

MRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist

MRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:

More information

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

EFFECTIVE SHARED CARE AGREEMENT (ESCA) WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic

More information

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP. Replaces: No previous version available. Management Committee 11 th March 2014

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP. Replaces: No previous version available. Management Committee 11 th March 2014 GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP Methylphenidate and Dexamfetamine in children and adolescents: SHARED CARE GUIDELINE Scope:

More information

Document Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers

Document Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers Document Details Title Shared Care Agreement Lisdexamfetamine Trust Ref No 1989-33708 Local Ref (optional) Main points the document covers The responsibilities of each partner entering into the shared

More information

SHARED CARE AGREEMENT

SHARED CARE AGREEMENT SHARED CARE AGREEMENT CNS Stimulants and other drugs for Attention Deficit Hyperactivity Disorder (ADHD) in Children (,, hydrochloride) Version: Date: Author: Status: Comment: 6 31.01.2014 Dr Peter Coleman

More information

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

EFFECTIVE SHARED CARE AGREEMENT (ESCA) WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: LICENSED MEDICATIONS FOR ADHD INDICATION/S COVERED: Attention Deficit Hyperactivity Disorder (ADHD) in Children Coastal West

More information

Worcestershire Area Prescribing Committee Guideline

Worcestershire Area Prescribing Committee Guideline Worcestershire Area Prescribing Committee Guideline Attention Deficit Hyperactivity Disorder (ADHD) in Adults, Adolescents and Children Prescribing Guidelines and Shared Care for GPs, locum doctors and

More information

Shared Care Agreement for Donepezil

Shared Care Agreement for Donepezil ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to

More information

Kiran Hewitt Katie Sims. Dr Alex Day. Reviewed By Ozma Tahir Lead Medicines Information and Clinical Economy Pharmacist, BHFT

Kiran Hewitt Katie Sims. Dr Alex Day. Reviewed By Ozma Tahir Lead Medicines Information and Clinical Economy Pharmacist, BHFT Prescribing Arrangements for the use of methylphenidate, atomoxetine, lisdexamfetamine and amfetamine in adult ADHD (attention deficit hyperactivity disorder) in Berkshire For all referrals of adults with

More information

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:

More information

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

More information

BNSSG Shared Care Guidance Please complete all sections

BNSSG Shared Care Guidance Please complete all sections NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please

More information

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2018. All rights reserved. Subject to Notice of rights

More information

North Central London Joint Formulary Committee

North Central London Joint Formulary Committee North Central London Joint Formulary Committee Shared Care Guideline Methylphenidate (immediate release and long acting), Atomoxetine, Dexamfetamine and Lisdexamfetamine for treatment of Adult Attention

More information

Prescribing classification: Amber with shared care. NOTES to the GP

Prescribing classification: Amber with shared care. NOTES to the GP SHARED CARE PRESCRIBING GUIDELINE LICENSED MEDICATIONS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDHOOD NOTE: to be used by practices participating in the locally commissioned

More information

Please note: Although some of these products are not licensed in adults NICE recommends them as treatment in adults

Please note: Although some of these products are not licensed in adults NICE recommends them as treatment in adults Methylphenidate, Dexamfetamine, Atomoxetine and Lisdexamphetamine Shared care guideline for the treatment of Attention Deficit Hyperactivity Disorder in children, young people and adults Please note: Although

More information

Shared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved by Joint Medicines Operational Group 1/12/17

Shared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved by Joint Medicines Operational Group 1/12/17 This policy statement is approved by Southport and Formby, and South Sefton CCGs Southport and Formby South Sefton Shared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved

More information

Prescribing framework for Dexamfetamine for Attention Deficit Hyperactive Disorder

Prescribing framework for Dexamfetamine for Attention Deficit Hyperactive Disorder Hull & East Riding Prescribing Committee Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)

More information

SHARED CARE AGREEMENT. between. Alder Hey Children's NHSFT and Liverpool CCG

SHARED CARE AGREEMENT. between. Alder Hey Children's NHSFT and Liverpool CCG This policy statement is approved by Liverpool CCG Halton Liverpool St Helens Warrington West Lancashire SHARED CARE AGREEMENT between Alder Hey Children's NHSFT and Liverpool CCG Methylphenidate (Ritalin,

More information

Shared Care Guidelines. Shared Care Guidelines for Attention Deficit Hyperactivity Disorder in children:

Shared Care Guidelines. Shared Care Guidelines for Attention Deficit Hyperactivity Disorder in children: Shared Care Guidelines Shared Care Guidelines for Attention Deficit Hyperactivity Disorder in children: BACKGROUND Attention Deficit Hyperactivity Disorder (ADHD) is a neuro-developmental condition affecting

More information

Protocol 02, v1.0, HMMC October of 22

Protocol 02, v1.0, HMMC October of 22 Protocol 02: Methylphenidate, atomoxetine, dexamfetamine and lisdexamfetamine prescribing and monitoring guidance for treatment of Attention Deficit Hyperactivity Disorder in children, young people and

More information

NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST

NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST SHARED CARE GUIDELINE: Methylphenidate, atomoxetine, dexamfetamine and lisdexamfetamine

More information

ADHD. Treatment of ADHD

ADHD. Treatment of ADHD Shared care guideline for the use of Methylphenidate, Dexamfetamine, Lisdexamfetamine dimesylate & Atomoxetine for the management of Attention Deficit Hyperactivity Disorder (ADHD) in Adults (18-64years)

More information

SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty

SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR mg TM ) for precocious puberty WORKING IN PARTNERSHIP WITH SHARED CARE PRESCRIBING GUIDELINE Triptorelin (Gonapeptyl Depot 3.75 mg TM, Decapeptyl SR 11.25 mg TM ) for precocious puberty NHS Surrey s Medicines Management Committee classification:

More information

ESCA: Cinacalcet (Mimpara )

ESCA: Cinacalcet (Mimpara ) ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details

More information

Effective Shared Care Agreement (ESCA) Methylphenidate (from age 6 years) Approved for Solihull locality only.

Effective Shared Care Agreement (ESCA) Methylphenidate (from age 6 years) Approved for Solihull locality only. Effective Shared Care Agreement (ESCA) Methylphenidate (from age 6 years) Approved for Solihull locality only. ESCA: For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as part of a comprehensive

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED

More information

Prescribing Framework for Lisdexamfetamine for Attention Deficit Hyperactivity Disorder

Prescribing Framework for Lisdexamfetamine for Attention Deficit Hyperactivity Disorder Hull & East Riding Prescribing Committee Prescribing Framework for Lisdexamfetamine for Attention Deficit Hyperactivity Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)

More information

THE SCHOOL SETTING INCLUDING THE ROLE OF COMMUNITY CHILD HEALTH MEDICAL AND SCHOOL NURSING SERVICES

THE SCHOOL SETTING INCLUDING THE ROLE OF COMMUNITY CHILD HEALTH MEDICAL AND SCHOOL NURSING SERVICES THIS GUIDELINE DESCRIBES THE PHARMACOLOGICAL MANAGEMENT OF Attention Deficit Hyperactivity Disorder IN THE SCHOOL SETTING INCLUDING THE ROLE OF COMMUNITY CHILD HEALTH MEDICAL AND SCHOOL NURSING SERVICES

More information

Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)

Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply

More information

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults Issued: September 2008 last modified: March 2013 NICE clinical guideline 72 guidance.nice.org.uk/cg72

More information

London Medicines Information Service

London Medicines Information Service London Medicines Information Service Extended-release methylphenidate a review of the pharmacokinetic profiles available March 2018 First authored by Martin Bradley (martin.bradley@gstt.nhs.uk) May 2016

More information

Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate)

Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate) Part VI: Summary of the risk management plan Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate) This is a summary of the risk management plan (RMP) for

More information

Prescribing Framework for Guanfacine Hydrochloride (Intuniv) for Attention Deficit Hyperactivity Disorder

Prescribing Framework for Guanfacine Hydrochloride (Intuniv) for Attention Deficit Hyperactivity Disorder Hull & East Riding Prescribing Committee Prescribing Framework for Guanfacine Hydrochloride (Intuniv) for Attention Deficit Hyperactivity Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use

More information

Essential Shared Care Agreement: Lithium

Essential Shared Care Agreement: Lithium Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed

More information

Nikki Mallinder on behalf of Linda Honey. Karen Thorburn Date: 04/10/18

Nikki Mallinder on behalf of Linda Honey. Karen Thorburn Date: 04/10/18 Agenda item: 7 ii Paper no: PCCC ic 20-18 Title of Report: Status: Committee: Venue: Update to the Attention Deficit Hyperactivity Disorder (ADHD) in Childhood) 12 monthly physical medication monitoring

More information

Shared Care Guidance. Vigabatrin

Shared Care Guidance. Vigabatrin North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.

More information

For children and adolescents and continued prescribing in patients transferred to adult services. For newly diagnosed adults

For children and adolescents and continued prescribing in patients transferred to adult services. For newly diagnosed adults SHARED CARE PROTOCOL FOR: METHYLPHENIDATE, ATOMOXETINE, LISDEXAMFETAMINE and DEXAMFETAMINE FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) For children and adolescents and continued

More information

ADHD. Medicines to help symptoms of adult attention deficit hyperactivity disorder (ADHD)

ADHD. Medicines to help symptoms of adult attention deficit hyperactivity disorder (ADHD) ADHD Medicines to help symptoms of adult attention deficit hyperactivity disorder (ADHD) This guide can help you to make a more informed choice about which medication may be best for you if you have been

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine

More information

SHARED CARE AGREEMENT: MELATONIN (CHILDREN)

SHARED CARE AGREEMENT: MELATONIN (CHILDREN) NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate

More information

BHR and Waltham Forest CCG GPs and NELFT Shared Care Guidelines

BHR and Waltham Forest CCG GPs and NELFT Shared Care Guidelines BHR and Waltham Forest CCG GPs and NELFT Shared Care Guidelines Shared Care Guidelines for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Working Age Adults Methylphenidate (Ritalin,

More information

Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information

Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the

More information

Version Control Summary Version Date Comments / changes 1.0 June November January 2009

Version Control Summary Version Date Comments / changes 1.0 June November January 2009 Document Control Summary Title Purpose of document Electronic file reference (authors) Electronic file reference (network or intranet) Status Draft 4 Version 1 Author(s) Name and position Circulated to

More information

Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder and Narcolepsy

Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder and Narcolepsy Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder and Narcolepsy Patient s Name: NHS Number: Patient s Address: (Use addressograph sticker) GP s Name:... Communication

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium atomoxetine capsules 10 mg to 60 mg (Strattera ) (153/05) Eli Lilly and Company Ltd No. 4 February 2005 The Scottish Medicines Consortium has completed its assessment of the

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine

More information

To approve Primary Care Commissioning Committees in Common Date: 9/11/18. NWS CCG 58 Church St, Weybridge, Surrey, KT13 8DP

To approve Primary Care Commissioning Committees in Common Date: 9/11/18. NWS CCG 58 Church St, Weybridge, Surrey, KT13 8DP Agenda item: 9 Paper no: PCCC ic 31-18 Title of Report: Status: Committee: Attention Deficit Hyperactivity Disorder (ADHD) in children 6-17 years old - 12 monthly review monitoring for CNS stimulants,

More information

1. Initial referral to specialist raising possibility of ADHD. 2. Provide medical history and perform physical examination if requested.

1. Initial referral to specialist raising possibility of ADHD. 2. Provide medical history and perform physical examination if requested. Shared Care Guidelines for Methylphenidate, Dexamfetamine, Atomoxetine, Lisdexamfetamine and Guanfacine for Attention Deficit Hyperactivity Disorder (ADHD) in Children, Adolescents and Adults Sharing of

More information

Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults

Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page

More information

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children

Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Shared Care Guideline for the treatment of Tourette s Syndrome and other tic disorders in children and adolescents. Scope: Version: Pennine Care NHS Foundation Trust NHS Bury NHS

More information

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Prescribing Framework for Galantamine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS

SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:

More information

Please note: Although some of these products are not licensed in adults NICE recommends them as treatment in adults

Please note: Although some of these products are not licensed in adults NICE recommends them as treatment in adults Methylphenidate, Dexamfetamine, Atomoxetine, Lisdexamphetamine and Guanfacine Shared care guideline for the treatment of Attention Deficit Hyperactivity Disorder in children, young people and adults Please

More information

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...

More information

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

EFFECTIVE SHARED CARE AGREEMENT (ESCA) EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: HYDROXYCHLOROQUINE INDICATION/S COVERED: active rheumatoid arthritis, juvenile idiopathic arthritis, discoid and systemic lupus erythematosus Coastal West

More information

Conroe ADHD Solutions

Conroe ADHD Solutions Diagnosis and Medical Management of ADD/ADHD How do we make the diagnosis of ADD/ADHD? We are very careful to be sure we have the diagnosis correct before considering treatment. In the past there were

More information

Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor

Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry

More information

Diagnosis and management of ADHD in children, young people and adults

Diagnosis and management of ADHD in children, young people and adults Issue date: September 2008 Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults NICE clinical guideline 72 Developed by the National Collaborating

More information

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6 in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014

Job Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due

More information

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance

More information

Opinion 3 October 2012

Opinion 3 October 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 3 October 2012 RITALIN 10 mg, tablet B/30 (CIP code: 34009 339 294 0-4) RITALIN LP 10 mg, sustained-release tablets

More information

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This

More information

Greater Manchester Interface Prescribing Group Shared Care Guideline

Greater Manchester Interface Prescribing Group Shared Care Guideline Greater Manchester Interface Prescribing Group Shared Care Guideline Shared Care Guideline for Melatonin Circadin Author(s)/Originator(s): Dr Rob Rifkin Paediatrician RI Adele Gothard Paediatric Pharmacist

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE

More information

New Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services

New Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services New Jersey Department of Children and Families Policy Manual Manual: CP&P Child Protection and Permanency Effective Volume: V Health Date: Chapter: A Health Services 1-11-2017 Subchapter: 1 Health Services

More information

ADHD Medication Shared Care Agreement

ADHD Medication Shared Care Agreement For the Treatment of Attention Deficit Hyperactivity Disorder in children aged 6 years of age and over AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways

More information

SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS

SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:

More information

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:

More information

RELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH

RELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH RELEVANT ACUTE TRUST LOGO WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley

More information

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to

More information

Physical health of children and adolescents

Physical health of children and adolescents Physical health of children and adolescents FR/CAP/02 What specialist child and adolescent psychiatrists need to know and do Faculty of Child and Adolescent Psychiatry, Royal College of Psychiatrists FACULTY

More information